

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

## Press Release



### **ASKA Pharmaceutical Holdings Group Recognized as Enterprise in Outstanding Organizations of KENKO Investment for Health Program (Large Enterprise Category) for Eighth Consecutive Year**

**TOKYO, March 9, 2026** - ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) announced that the Company was recognized as an “Enterprise in the 2026 Outstanding Organizations of KENKO Investment for Health Program (Large Enterprise Category)”, a joint initiative of the Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi on March 9, 2026.

As the core company of ASKA Pharmaceutical Holdings Group (hereinafter “Group”), ASKA Pharmaceutical Co., Ltd. has been certified for eight consecutive years, and ASKA Pharmaceutical Holdings Co., Ltd. has been certified for five consecutive years.

Based on the Company's corporate philosophy, “Contribute toward the improvement of people's health and progress in society through the development of innovative products,” the Group is promoting corporate activities with the aim of becoming a total healthcare company that develops businesses in the areas of prevention, testing/diagnosis, treatment, and prognosis. The Group believes that “human resources” are the driving force behind these corporate activities, and it aims to further improve productivity and creativity by maintaining and improving employee health and promoting work style reform from a managerial perspective.

In FY2025, breast and cervical cancer screenings for women and PSA testing for men were conducted during health checkups, and “What Adolescent Men, Women, and Parents Should Know” was the topic of an in-house training session to improve health literacy. In addition, the number of employees eligible for the “Work Support Fund” system, which aims to foster an organizational culture that positively accepts colleagues' life events, has expanded, and a culture in which employees who support colleagues on leave are valued throughout the organization is steadily taking root.

The Group will continue to promote health and productivity management from various perspectives so that employees, the organization, and society can mutually share the valuable happiness of health.



**Enterprises in the 2026 Outstanding Organizations of KENKO Investment for Health Program (Large Enterprise Category)**

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

### **The Company's Health and Productivity Management Initiatives**

For more information on the ASKA Pharmaceutical Holdings Group's Health and productivity management, please visit the website.

<https://www.aska-pharma-hd.co.jp/english/csr/social/health.html>

### **ASKA Pharmaceutical Co., Ltd. – Health Lab Mint<sup>+</sup> for Women's health**

To learn more about the Mint<sup>+</sup> Women's Health Lab initiatives, please visit the website.

<https://www.aska-pharma.co.jp/mint/> (Japanese version only)

**Enterprises in the Outstanding Organizations of KENKO Investment for Health Program** were certified by the Nippon Kenko Kaigi for recognizing companies that implement excellent health and productivity management in cooperation with insurers.

---

### **Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)